Pathos AI raises $237M to expand its oncology pipeline
A $237 million Series E values Pathos AI at approximately $3 billion and supports its AI platform and clinical oncology programmes.
What happened
Pathos AI closed a $237 million Series E at an approximately $3 billion post-money valuation. Bristol Myers Squibb led the round, which will support Pathos Foundry and the development of four oncology assets, including work toward a registrational study for JSKN-016.
Why it matters
The financing combines strategic pharmaceutical backing with an AI-native approach to portfolio selection and clinical development. It gives Pathos substantial resources to advance several programmes simultaneously.
The bigger picture
The round reflects strong investor interest in applying AI to drug development. Funding and platform capability do not establish clinical success; trial results and regulatory progress remain the meaningful tests.